Nine meta-analyses studied interventions for anemia in CKD, of which only meta-regression analyses of RCTs achieved statistical significance, which shows that a higher dose of erythropoietin stimulating agents was associated with higher mortality [39]. This evidence concerns the gene EPO and anemia (phenotype).